GMT Stock Overview
Researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genomtec S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł7.95 |
| 52 Week High | zł14.40 |
| 52 Week Low | zł6.50 |
| Beta | 0.25 |
| 1 Month Change | 7.72% |
| 3 Month Change | 6.00% |
| 1 Year Change | -23.92% |
| 3 Year Change | -13.59% |
| 5 Year Change | n/a |
| Change since IPO | -41.33% |
Recent News & Updates
Shareholder Returns
| GMT | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 2.1% | -3.4% | -2.6% |
| 1Y | -23.9% | -25.9% | -4.9% |
Return vs Industry: GMT exceeded the Polish Biotechs industry which returned -25.9% over the past year.
Return vs Market: GMT underperformed the Polish Market which returned -4.9% over the past year.
Price Volatility
| GMT volatility | |
|---|---|
| GMT Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 8.7% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: GMT's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: GMT's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 17 | Miron Tokarski | www.genomtec.com |
Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus.
Genomtec S.A. Fundamentals Summary
| GMT fundamental statistics | |
|---|---|
| Market cap | zł105.93m |
| Earnings (TTM) | -zł11.58m |
| Revenue (TTM) | zł1.00k |
Over9,999x
P/S Ratio-9.2x
P/E RatioIs GMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMT income statement (TTM) | |
|---|---|
| Revenue | zł1.00k |
| Cost of Revenue | zł2.63m |
| Gross Profit | -zł2.63m |
| Other Expenses | zł8.95m |
| Earnings | -zł11.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | -263,000.00% |
| Net Profit Margin | -1,157,600.00% |
| Debt/Equity Ratio | 4.3% |
How did GMT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genomtec S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|